Editing TUDCA (tauroursodeoxycholic acid)

Jump to: navigation, search

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.

The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
Latest revision Your text
Line 1: Line 1:
 
[[Information on nutritional supplements people with ALS have been taking]]
 
[[Information on nutritional supplements people with ALS have been taking]]
  
* [https://en.wikipedia.org/wiki/Tauroursodeoxycholic_acid Wikipedia page]
+
[https://en.wikipedia.org/wiki/Tauroursodeoxycholic_acid Wikipedia page]
 
 
* [http://examine.com/supplements/Tauroursodeoxycholic+Acid/ Examine.com]
 
 
 
* [http://www.tandfonline.com/doi/abs/10.3109/21678421.2014.931010 ALSUntangled evaluation report]
 
  
 
== Effects on ALS ==
 
== Effects on ALS ==
  
TUDCA is a taurine-conjugated form of ursodiol and is commonly used for treatment of chronic cholestatic liver diseases and for gallstone. It possesses many additional ancillary features, including the inhibition of mitochondrial-associated apoptosis through different mechanisms. It has been shown that, in a cellular model of superoxide dismutase 1 neurodegeneration, glycine-conjugated UDCA inhibits nitrite production and prevents matrix metallopeptidase 9 activation {{#pmid:25664595|elia2015}}.
+
TUDCA is commonly used for treatment of chronic cholestatic liver diseases and for gallstone. It possesses many additional ancillary features, including the inhibition of mitochondrial-associated apoptosis through different mechanisms. It has been shown that, in a cellular model of superoxide dismutase 1 neurodegeneration, glycine-conjugated UDCA inhibits nitrite production and prevents matrix metallopeptidase 9 activation [1].
  
At the end of the 54-week treatment period, patients in the TUDCA group had a mean ALSFRS-R score corresponding to that of the placebo group at week 36. This suggests that a 1-year TUDCA treatment may slow ALS deterioration by 18 weeks and leads us to suppose that a longer duration of treatment may produce an even more accentuated between-group divergence {{#pmid:25664595|elia2015}}.
+
At the end of the 54-week treatment period, patients in the TUDCA group had a mean ALSFRS-R score corresponding to that of the placebo group at week 36. This suggests that a 1-year TUDCA treatment may slow ALS deterioration by 18 weeks and leads us to suppose that a longer duration of treatment may produce an even more accentuated between-group divergence [1].
  
This study was designed to assess the effects of UDCA on oxidative injury and antioxidative systems in cultured rat hepatocytes. The viability of the hepatocytes dose-dependently decreased after hydrogen peroxide or cadmium administration. Pretreatment with UDCA significantly prevented this decrease in viability. The amounts of glutathione (GSH) and protein thiol increased significantly, but the activities of antioxidative enzymes such as superoxide dismutase, glutathione peroxidase and catalase were unchanged in UDCA-treated hepatocytes. The mRNA levels of gamma-glutamylcysteine synthetase and metallothionein (MT) were significantly higher in UDCA-treated hepatocytes than in controls. In conclusion, UDCA increased hepatocyte levels of GSH and thiol-containing proteins such as MT, thereby protecting hepatocytes against oxidative injury. {{#pmid:10491327|mitsuyoshi1999}}
 
  
UDCA significantly (p<0.05) restored GSH and total sulfhydryl, and decreased MDA levels. T-AOC and the mean activities of the antioxidant enzymes were elevated following treatment with UDCA. {{#pmid:22275806|qi2012}}
+
== References ==
 
 
== Cautions ==
 
  
According to Examine.com: "If using TUDCA for treating an alcohol-abused liver, be aware of the temporal relationship needed. Co-incubation (same time) or rehabilitative (after the matter) usage of TUDCA may be protective of the liver while pre-loading TUDCA before drinking may be harmful to the liver."
+
[1]
 +
<bibtex>
 +
@article{Elia2015,
 +
abstract = {BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).
  
<a href=http://lasix.mom>lasix and alcohol</a> Interesting way to normal menstrual cycle
+
METHODS: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead-in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15\% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) slope during the treatment period compared to the lead-in phase]. Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, comparison of the linear regression slopes for ALSFFRS-R mean scores and the occurrence of adverse events.
 
 
== References ==
 
  
 +
RESULTS: Tauroursodeoxycholic acid was well tolerated; there were no between-group differences for adverse events. The proportion of responders was higher under TUDCA (87\%) than under placebo (P = 0.021; 43\%). At study end baseline-adjusted ALSFRS-R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).
  
[[Category:Supplement data pages]]
+
CONCLUSIONS: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.},
 +
author = {Elia, A E and Lalli, S and Monsurr\`{o}, M R and Sagnelli, A and Taiello, A C and Reggiori, B and {La Bella}, V and Tedeschi, G and Albanese, A},
 +
doi = {10.1111/ene.12664},
 +
issn = {1468-1331},
 +
journal = {European journal of neurology : the official journal of the European Federation of Neurological Societies},
 +
mendeley-groups = {taurine},
 +
month = feb,
 +
pmid = {25664595},
 +
title = {{Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.}},
 +
url = {http://www.ncbi.nlm.nih.gov/pubmed/25664595},
 +
year = {2015}
 +
}
 +
</bibtex>

Please note that all contributions to MyWiki may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see MyWiki:Copyrights for details). Do not submit copyrighted work without permission!

To protect the wiki against automated edit spam, we kindly ask you to solve the following CAPTCHA:

Cancel | Editing help (opens in new window)

Template used on this page: